AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19346113 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric placebo matched for macronutrient composition
Number of subjects: 33
Study 17130849 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lidocaine per nostril
Number of subjects: 20
Study 17130849 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine per nostril
Number of subjects: 20
Study 17130849 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg lidocaine per nostril
Number of subjects: 20
Study 17130849 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 20
Study 15101566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride augmentation (600 mg/day) with olanzapine
Number of subjects: 17
Study 15101566 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy (control group)
Number of subjects: 17
Study 11339914 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of pelvic floor exercises with biofeedback and electrostimulation (n = 51)
Number of subjects: 107
Study 11339914 — intervention group
Group type: COMPARATOR
Intervention: No training (n = 56)
Number of subjects: 107
Study 9090591 — intervention group
Group type: EXPERIMENTAL
Intervention: RARE (rapid acquisition with relaxation enhancement)
Number of subjects: 7
Study 9090591 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH (fast low‐angle shot)
Number of subjects: 7
Study 7525169 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 18
Study 2439854 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stent insertion
Number of subjects: 75
Study 2439854 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous stent insertion
Number of subjects: 75
Study 31818823 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg every 12 hours (q12h)
Number of subjects: 102
Study 31818823 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg every 12 hours (q12h)
Number of subjects: 102
Study 31818823 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg every 8 hours (q8h)
Number of subjects: 102
Study 31818823 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin (all doses)
Number of subjects: 102
Study 30431387 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib
Number of subjects: 100
Study 30431387 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV+Hib
Number of subjects: 100
Study 25415413 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling (20 minutes immediately, 24, and 48 hours post-exercise)
Number of subjects: 8
Study 25415413 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 8
Study 25415413 — intervention group
Group type: COMPARATOR
Intervention: No foam rolling (control)
Number of subjects: 8
Study 24267040 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched meal
Number of subjects: 21
Study 24267040 — intervention group
Group type: COMPARATOR
Intervention: Butter-enriched meal
Number of subjects: 21
Study 24267040 — intervention group
Group type: COMPARATOR
Intervention: Olive oil-enriched meal
Number of subjects: 21
Study 21843716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication at hernia repair
Number of subjects: 79
Study 21843716 — intervention group
Group type: COMPARATOR
Intervention: Regular hernia closure
Number of subjects: 79
Study 19281877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for surgery
Number of subjects: 30
Study 19281877 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed patients
Number of subjects: 30
Study 19281877 — intervention group
Group type: COMPARATOR
Intervention: Clinically treated patients
Number of subjects: 30
Study 17577103 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg BID
Number of subjects: 117
Study 17577103 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 200 mg BID
Number of subjects: 117
Study 17577103 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 160 mg BID
Number of subjects: 117
Study 17577103 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (various dosages)
Number of subjects: 117
Study 17577103 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (supratherapeutic dosages)
Number of subjects: 117
Study 15701933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive practice-based parenting programme
Number of subjects: 42
Study 15701933 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study 11154253 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention including a series of simple exercises and repositioning of the kneecap using tape.
Number of subjects: 20
Study 11154253 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 20
Study 9522134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (50 mg) intra‐articular (IA)
Number of subjects: 103
Study 9522134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of 0.1% preservative free morphine chloride in saline
Number of subjects: 103
Study 9522134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of 0.1% preservative free morphine chloride in 0.25% bupivacaine
Number of subjects: 103
Study 9522134 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 103
Study 7855606 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for postoperative infections
Number of subjects: 32
Study 7855606 — intervention group
Group type: COMPARATOR
Intervention: Patients with superficial wound infection
Number of subjects: 32
Study 7855606 — intervention group
Group type: COMPARATOR
Intervention: Patients with deep wound infection
Number of subjects: 32
Study 2478604 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or 100 times the concentration of allergen required for 4+ early intradermal reaction
Number of subjects: 24
Study 2478604 — intervention group
Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 24
Study 799983 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-17, 21-dipropionate and salicylic acid treatment
Number of subjects: 0
Study 31502392 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% metformin lotion
Number of subjects: 40
Study 31502392 — intervention group
Group type: COMPARATOR
Intervention: Triple combination cream (TCC) (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%)
Number of subjects: 40
Study 31605113 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV/ΔNS2/Δ1313/I1314L vaccine at 106 PFU
Number of subjects: 30
Study 31605113 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV/ΔNS2/Δ1313/I1314L vaccine at 105 PFU
Number of subjects: 30
Study 31605113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27756788 — intervention group
Group type: EXPERIMENTAL
Intervention: Urelumab 0.1 mg/kg every 3 weeks
Number of subjects: 346
Study 27756788 — intervention group
Group type: EXPERIMENTAL
Intervention: Urelumab doses between 1 and 15 mg/kg every 3 weeks
Number of subjects: 346
Study 27756788 — intervention group
Group type: EXPERIMENTAL
Intervention: Urelumab doses ≥1 mg/kg
Number of subjects: 346
Study 25103549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Number of subjects: 120
Study 25103549 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 120
Study 24283127 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel beads containing Eimeria oocysts
Number of subjects: 0
Study 24283127 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray vaccination with Eimeria oocysts
Number of subjects: 0
Study 24283127 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel beads or spray vaccination
Number of subjects: 0
Study 24283127 — intervention group
Group type: COMPARATOR
Intervention: All immunized groups
Number of subjects: 0
Study 21487215 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 1678
Study 21487215 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants (FF)
Number of subjects: 1678
Study 21487215 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BF and FF infants
Number of subjects: 1678
Study 21487215 — intervention group
Group type: COMPARATOR
Intervention: Timing of introduction of potentially allergenic foods
Number of subjects: 1678
Study 18029002 — intervention group
Group type: EXPERIMENTAL
Intervention: Concealed question interpretation
Number of subjects: 0
Study 18029002 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical verbs presented in isolation
Number of subjects: 0
Study 16751153 — intervention group
Group type: EXPERIMENTAL
Intervention: Detemir
Number of subjects: 0
Study 12742981 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF adenovirus (VEGF‐Adv, 2x10(10) pfu)
Number of subjects: 103
Study 12742981 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF plasmid liposome (VEGF‐P/L; 2000 microg of DNA with 2000 microL of DOTMA:DOPE [1:1 wt/wt])
Number of subjects: 103
Study 12742981 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (Control)
Number of subjects: 103
Study 10694896 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-isosorbide mononitrate (ISMO) 20 mg
Number of subjects: 18
Study 10694896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11322264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus didanosine
Number of subjects: 29
Study 11322264 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea plus zidovudine
Number of subjects: 29
Study 11322264 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea monotherapy
Number of subjects: 29
Study 11322264 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 29
Study 11322264 — intervention group
Group type: COMPARATOR
Intervention: Didanosine monotherapy
Number of subjects: 29
Study 8385040 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 9
Study 8385040 — intervention group
Group type: COMPARATOR
Intervention: Calcium polycarbophil
Number of subjects: 9
Study 8385040 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 9
Study 8385040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3699924 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (went up by train/road transport to 3658 m)
Number of subjects: 50
Study 3699924 — intervention group
Group type: COMPARATOR
Intervention: Group B (reached the same height after 8 days of acclimatisation en route)
Number of subjects: 50
Study 30412360 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF in fasted conditions
Number of subjects: 120
Study 30412360 — intervention group
Group type: COMPARATOR
Intervention: D/C/F/TAF after a standardized high-fat breakfast
Number of subjects: 120
Study 30412360 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 120
Study 29524621 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (35 mg/kg p.o.)
Number of subjects: 19
Study 29524621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 26344811 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion preload containing 2 μm oil droplets
Number of subjects: 34
Study 26344811 — intervention group
Group type: COMPARATOR
Intervention: Emulsion preload containing 50 μm oil droplets
Number of subjects: 34
Study 24446590 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gingival displacement (gingival cord + 25% AlCl3 astringent gel)
Number of subjects: 12
Study 24446590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordless gingival displacement (15% AlCl3 astringent-based paste)
Number of subjects: 12
Study 22562021 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab high dose (40 mg or 20 mg for body weight >/=40 kg or <40 kg; n = 93)
Number of subjects: 192
Study 22562021 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab low dose (20 mg or 10 mg for body weight >/=40 kg or <40 kg; n = 95)
Number of subjects: 192
Study 22562021 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as patients not receiving adalimumab)
Number of subjects: 192
Study 20059776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention program (medical interventions and optional behavior-change interventions)
Number of subjects: 314
Study 20059776 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 17617522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 4626
Study 15570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 100 mg bid
Number of subjects: 42
Study 15570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 200 mg bid
Number of subjects: 42
Study 15570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg bid
Number of subjects: 42
Study 15570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 600 mg bid
Number of subjects: 42
Study 15570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (all doses)
Number of subjects: 42
Study 15570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (responders)
Number of subjects: 42
Study 11213010 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg prednisolone daily in two divided oral doses
Number of subjects: 25
Study 11213010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9625686 — intervention group
Group type: COMPARATOR
Intervention: Short technical reports
Number of subjects: 57
Study 9625686 — intervention group
Group type: EXPERIMENTAL
Intervention: Long clinical reports
Number of subjects: 57
Study 8158537 — intervention group
Group type: EXPERIMENTAL
Intervention: B cells secreting IgG anti-gp160/120 antibodies
Number of subjects: 0
Study 8158537 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic response in HIV-infected patients
Number of subjects: 0
Study 8158537 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic response in gp160/gp120-immunized volunteers
Number of subjects: 0
Study 3139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and transfusion
Number of subjects: 1100
Study 3139387 — intervention group
Group type: COMPARATOR
Intervention: No transfusion (with or without surgery)
Number of subjects: 1100
Study 3139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused group
Number of subjects: 1100
Study 3139387 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including transfusion and surgery)
Number of subjects: 1100
Study 3139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 1100
Study 3139387 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent hepatitis cases
Number of subjects: 1100
Study 29617468 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of snack bars or fast-food outlets
Number of subjects: 2195
Study 29617468 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of butchers
Number of subjects: 2195
Study 28787504 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy
Number of subjects: 364
Study 28787504 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 364
Study 28787504 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory secondary outcomes
Number of subjects: 364
Study 26579561 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy
Number of subjects: 320
Study 26579561 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 320
Study 26579561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarification‐oriented psychotherapy
Number of subjects: 320
Study 24247643 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 42
Study 24247643 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw
Number of subjects: 42
Study 21530253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoplastic surgery
Number of subjects: 90
Study 21530253 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery without breast reconstruction (control group)
Number of subjects: 90
Study 18979376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic body expressions of anger (videos)
Number of subjects: 0
Study 18979376 — intervention group
Group type: COMPARATOR
Intervention: Still body expressions of anger (stills)
Number of subjects: 0
Study 18979376 — intervention group
Group type: COMPARATOR
Intervention: Neutral body expressions (stills/videos)
Number of subjects: 0
Study 16798925 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium screens (low tube potential setting)
Number of subjects: 201
Study 16798925 — intervention group
Group type: COMPARATOR
Intervention: Regular film-screen combinations (high tube potential settings)
Number of subjects: 201
Study 16798925 — intervention group
Group type: COMPARATOR
Intervention: Digital system (irrespective of exposure)
Number of subjects: 201
Study 16798925 — intervention group
Group type: COMPARATOR
Intervention: Digital system
Number of subjects: 201
Study 16798925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarater agreement
Number of subjects: 201
Study 12699507 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 33
Study 12699507 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation with Pressure Support (SIMV-PC/PS)
Number of subjects: 33
Study 10675054 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language version of the Health-Promoting Lifestyle Profile II
Number of subjects: 60
Study 9509822 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 35
Study 9509822 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 8465379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 150
Study 8465379 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 150
Study 4054138 — intervention group
Group type: EXPERIMENTAL
Intervention: PY-108-068 75 mg
Number of subjects: 19
Study 4054138 — intervention group
Group type: EXPERIMENTAL
Intervention: PY-108-068 150 mg
Number of subjects: 19
Study 4054138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31390198 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic FCI-FRI scheme
Number of subjects: 5
Study 31390198 — intervention group
Group type: COMPARATOR
Intervention: Multinomial FCI-FRI scheme
Number of subjects: 5
Study 31390198 — intervention group
Group type: COMPARATOR
Intervention: Original FCIQMC algorithm
Number of subjects: 5
Study 29619643 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy for Child Abuse and Neglect (MST‐CAN)
Number of subjects: 86
Study 29619643 — intervention group
Group type: COMPARATOR
Intervention: Enhanced outpatient treatment
Number of subjects: 86
Study 26852290 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative model (PPCM)
Number of subjects: 169
Study 26852290 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 169
Study 1590572 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg and flunitrazepam 0.5 mg p.o. given at 10:00 p.m. on the evening prior to surgery
Number of subjects: 38
Study 1590572 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam alone (Control)
Number of subjects: 38
Study 1590572 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine treatment group
Number of subjects: 38
Study 1590572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 22108447 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg nocte)
Number of subjects: 311
Study 22108447 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg nocte)
Number of subjects: 311
Study 20438539 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of sevelamer and calcium carbonate
Number of subjects: 14
Study 20438539 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of sevelamer and calcium carbonate
Number of subjects: 14
Study 18777767 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscented Nasonex
Number of subjects: 216
Study 18777767 — intervention group
Group type: COMPARATOR
Intervention: Scented Nasonex
Number of subjects: 216
Study 15963197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg once daily for 12 weeks
Number of subjects: 60
Study 15963197 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 12372452 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog (GnRH‐a) therapy for 6 months after surgery
Number of subjects: 110
Study 12372452 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of ART alone immediately after surgery
Number of subjects: 110
Study 10631414 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P50: propofol 1% 10 ml/thiopentone 2.5% 10 ml
Number of subjects: 90
Study 10631414 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P75: propofol 1% 15 ml/thiopentone 2.5% 5 ml
Number of subjects: 90
Study 10631414 — intervention group
Group type: COMPARATOR
Intervention: Group P100: propofol 1% 20 ml/lignocaine 1% 4 ml
Number of subjects: 90
Study 7860943 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 45) received instruction on reducing their intake of fat using current dietary recommendations.
Number of subjects: 61
Study 7860943 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 61
Study 2013178 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of acute sublingual nitrendipine
Number of subjects: 11
Study 2013178 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oxygen application at rest
Number of subjects: 11
Study 2013178 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of nitrendipine once daily for 3 weeks
Number of subjects: 11
Study 6496911 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lignocaine and prilocaine cream applied for 20 minutes or longer
Number of subjects: 114
Study 6496911 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lignocaine and prilocaine cream
Number of subjects: 114
Study 6496911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114